Opioid Use, Polysubstance Abuse, Tobacco Use
Conditions
Brief summary
The purpose of this study is to 1) examine barriers and facilitators to implementation of MI and MORE for polysubstance use and evaluate strategies for optimizing training, fidelity, and clinic uptake, and 2) evaluate patient outcomes related to the effectiveness of MORE decreasing opioid, tobacco, and other drug use.
Interventions
OTHERMORE and MI and NRT
Eight group Mindfulness Oriented Recovery Enhancement sessions and one motivational interviewing session and nicotine replacement therapy.
OTHERMORE and No MI and NRT
Eight group Mindfulness Oriented Recovery Enhancement sessions and nicotine replacement therapy.
OTHERSupport Group and MI and NRT
Eight group support group sessions and one motivational interviewing session and nicotine replacement therapy.
OTHERSupport Group and No MI and NRT
Eight group support group sessions and and nicotine replacement therapy.
Sponsors
Rutgers, The State University of New Jersey
University of Utah
National Institute on Drug Abuse (NIDA)
Study design
Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* English-speaking * Age ≥18 * Currently on methadone; and 4) currently smoke cigarettes.
Exclusion criteria
* Severe cognitive impairment (score \>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen) * Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire) * Inability to attend or fully participate in intervention sessions or assessments * Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33 * Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling * Any contraindications for NRT * Currently or soon planning to be pregnant or breastfeeding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Days of Drug Use | Baseline through 52 weeks. | Number of days of drug use as measured by self-reported days of use and biochemically verified use via drug screen. |
| Days of Tobacco Use | Baseline through 52 weeks. | Number of days of tobacco use as measured by self-reported days of use and biochemically verified use via expired carbon monoxide. |
Countries
United States
Contacts
CONTACTNina Cooperman, PsyD
CONTACTEric Garland, PhD
PRINCIPAL_INVESTIGATORNina Cooperman, PsyD
Rutgers Robert Wood Johnson Medical School
Outcome results
None listed